John Cumming

Director/Board Member at T2 BIOSYSTEMS, INC.

Net worth: 267 $ as of 2024-05-30

78 year

100 connections

Health Technology

Consumer Services

Commercial Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
John Sperzel	M	60	T2 BIOSYSTEMS, INC.	4 years
Stephen MacMillan	M	60	HOLOGIC, INC.	11 years
Eugene H. Vetter	M	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	14 years
Matthew McKillip	M	-	T2 BIOSYSTEMS, INC.	-
Sally Crawford	F	70	HOLOGIC, INC.	17 years
David MacKeen	M	-	Bentley University	17 years
James W. Vetter	M	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	14 years
Ninfa Saunders	M	72	T2 BIOSYSTEMS, INC.	4 years
Scott Garrett	M	74	HOLOGIC, INC.	11 years
Robin Toft	F	63	T2 BIOSYSTEMS, INC.	4 years
Michael Gibbs	M	53	T2 BIOSYSTEMS, INC.	10 years
John Sprague	M	65	T2 BIOSYSTEMS, INC.	6 years
Seymour Liebman	M	74	T2 BIOSYSTEMS, INC.	8 years
Christiana Stamoulis	F	53	HOLOGIC, INC.	13 years
Laura Adams	F	67	T2 BIOSYSTEMS, INC.	3 years
Karleen Oberton	F	54	HOLOGIC, INC.	18 years
David Elsbree	M	76	T2 BIOSYSTEMS, INC.	10 years
Kelley Morgan	F	-	T2 BIOSYSTEMS, INC.	10 years
Patricia Flynn	F	74	Bentley University	48 years
William Pappas	M	-	Bentley University	-
Monica Berthelot	F	-	HOLOGIC, INC.	12 years
Roger Smith	M	59	T2 BIOSYSTEMS, INC.	10 years
Richard Gnospelius	M	-	Bentley University	-
Jeff Coyne	M	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	-
Gordon McLenithan	M	-	Bentley University	-
Darryl Poole	M	-	Bentley University	-
Frank Kelly	M	-	Bentley University	-
Deborah Millin	F	-	Bentley University	-
Nickolas Stavropoulos	M	66	Bentley University	-
Brett Giffin	M	66	T2 BIOSYSTEMS, INC.	3 years
Brian Zino	M	72	Bentley University	13 years
George W. Carmany	M	84	Bentley University	-
Patrick J. Gnazzo	M	77	Bentley University	-
Debora Spar	M	60	Bentley University	-
Andrew J. Hajducky	M	70	Bentley University	-
Michael J. Cyrus	M	68	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	6 years
John Poduska	M	86	Bentley University	-
Dan A. Keshian	M	-	Bentley University	-
Alan P. Cleveland	M	-	Bentley University	-
Robert Badavas	M	71	Bentley University	19 years
Mark B. Skaletsky	M	75	Bentley University	-
Robert R. Anderson	M	86	Bentley University	-
Raul Claure	M	52	Bentley University	-
Tracy A. Sykes	F	-	Transmed7 LLC Transmed7 LLC Medical SpecialtiesHealth Technology Transmed7 LLC is a medical and technology-based organization that focuses on developing innovative, minimally-invasive medical devices for doctors and their patients. The private company is based in Phoenix, AZ. The company's portfolio of next-generation platform devices is expected to be market leaders in oncology, regenerative medicine, and cardiovascular disease. Transmed7's business plan and structure enable these new transformational technologies to move from rapid development through commercial manufacturing and market deployment. The company's transformational forward-coring, zero5 biopsy devices improve patient care with broad applications to breast, soft tissue, endoscopy, laparoscopy, robotics, vascular, bone marrow, and more. The company was founded in 2010 by Eugene H. Vetter, James W. Vetter. Eugene H. Vetter has been the CEO since 2010.	-
William Freda	M	71	Bentley University	-
Elizabeth Rainoff	F	-	Bentley University	-

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
S. David Ellenbogen	M	-	HOLOGIC, INC.	24 years
Robert Cascella	M	69	HOLOGIC, INC.	10 years
John McDonough	M	65	T2 BIOSYSTEMS, INC.	14 years
Elaine S. Ullian	F	76	HOLOGIC, INC.	19 years
David LaVance	M	70	HOLOGIC, INC.	-
Michael Cima	M	64	T2 BIOSYSTEMS, INC.	14 years
Mark Joseph Casey	M	60	HOLOGIC, INC.	7 years
Wayne L. Wilson	M	75	HOLOGIC, INC.	9 years
Michael J. Watts	M	-	HOLOGIC, INC.	-
Adrian Jones	M	59	T2 BIOSYSTEMS, INC.	4 years
Thomas Carella	M	49	T2 BIOSYSTEMS, INC.	3 years
Darlene Deptula-Hicks	F	66	T2 BIOSYSTEMS, INC.	1 years
Alan Crane	M	60	T2 BIOSYSTEMS, INC.	8 years
David Harding	M	58	T2 BIOSYSTEMS, INC. HOLOGIC, INC.	2 years
Robert Langer	M	74	T2 BIOSYSTEMS, INC.	8 years
Stanley Lapidus	M	75	T2 BIOSYSTEMS, INC.	12 years
Josh Bilenker	M	52	T2 BIOSYSTEMS, INC.	6 years
Thierry Bernard	M	60	T2 BIOSYSTEMS, INC.	3 years
Nancy L. Leaming	F	76	HOLOGIC, INC.	14 years
Jody Campbell	M	-	HOLOGIC, INC.	17 years
Steven Williamson	M	51	HOLOGIC, INC.	5 years
Bret Christensen	M	53	HOLOGIC, INC.	10 years
Jason Cervi	M	45	HOLOGIC, INC.	1 years
Anthony Pare	M	62	T2 BIOSYSTEMS, INC.	-
Alec Barclay	M	43	T2 BIOSYSTEMS, INC.	6 years
Constance Bridges	F	-	HOLOGIC, INC.	6 years
Joanne Spadoro	M	65	T2 BIOSYSTEMS, INC.	2 years
Joel Centeno	M	-	HOLOGIC, INC.	5 years
Stacy Feld	F	51	T2 BIOSYSTEMS, INC.	4 years
Shawn Lynch	M	-	T2 BIOSYSTEMS, INC.	1 years
Sharon L. Smith	F	-	HOLOGIC, INC.	12 years
Mark D. Myslinski	M	67	HOLOGIC, INC.	-
Richard Golin	M	71	HOLOGIC, INC.	1 years
Michael A. Pfaller	M	73	T2 BIOSYSTEMS, INC.	4 years
Robb Paul Hesley	M	61	HOLOGIC, INC.	4 years
Carl Hull	M	66	HOLOGIC, INC.	1 years
John Bellano	M	56	HOLOGIC, INC.	1 years
Jeffrey Hawkins	M	46	HOLOGIC, INC.	1 years
Peter C. Kershaw	M	70	HOLOGIC, INC.	3 years
Arthur G. Lerner	M	83	HOLOGIC, INC.	2 years
Jorge Garces	M	52	HOLOGIC, INC.	4 years
Laurie L. Fajardo	M	68	HOLOGIC, INC.	1 years
Howard Doran	M	63	HOLOGIC, INC.	3 years
Michael Levitz	M	50	HOLOGIC, INC.	2 years
William A. Peck	M	91	HOLOGIC, INC.	15 years
Gregory Hamilton	M	54	HOLOGIC, INC.	1 years
Patrick Sullivan	M	72	HOLOGIC, INC.	1 years
Daniel Levangie	M	73	HOLOGIC, INC.	1 years
C. William McDaniel	M	82	HOLOGIC, INC.	1 years
Maurice L. Castonguay	M	72	T2 BIOSYSTEMS, INC.	1 years
Mark Duerst	M	-	HOLOGIC, INC.	22 years
Peter K. Soltani	M	63	HOLOGIC, INC.	-
Steven L. Nakashige	M	-	HOLOGIC, INC.	8 years
Ed Hutchinson	M	-	HOLOGIC, INC.	5 years

Statistics

Country	Connections	% of total
United States	100	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections